Trials / Terminated
TerminatedNCT03465709
Pegcetacoplan (APL-2) in Neovascular AMD
An 18-Month Phase Ib/II Multi-Center, Open Label Study to Evaluate the Safety of Intravitreal APL-2 Therapy in Patients With Neovascular Age-Related Macular Degeneration (AMD)
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Apellis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
Safety Assessment of Pegcetacoplan in Patients with Neovascular AMD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegcetacoplan | Study Drug |
Timeline
- Start date
- 2018-02-14
- Primary completion
- 2019-04-05
- Completion
- 2019-04-05
- First posted
- 2018-03-14
- Last updated
- 2020-09-16
- Results posted
- 2020-09-16
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03465709. Inclusion in this directory is not an endorsement.